The Blackstone Group, a major US private equity firm, has announced the acquisition of Takeda Consumer Healthcare Company (TCHC), a subsidiary of Takeda Pharmaceutical. Investment funds and other industries have been putting out feelers toward the pharmaceutical sector in recent…
HOME > ACADEMIA
ACADEMIA
- Kyoto Univ. to Commence Trial of Drug Candidate Discovered in iPS Cells Research for Rare Bone Disease
August 3, 2017
- Drug Vial Optimization Reduces Drug Expenditure, with Biggest Savings for Opdivo: Study
August 2, 2017
- Hypertension Treatment Guidelines for Elderly Finalized with Recommendations on Dosage Reduction, Discontinuation
July 21, 2017
- JSHR to Conduct 20-Year Follow-Up Study in Up to 100,000 Patients to Determine Efficacy of H. Pylori Eradication Therapy at Preventing Stomach Cancer
July 14, 2017
- New Treatment GL for Advanced HCC to Be Issued in October, Will Recommend Nexavar for 1st-Line Treatment
July 11, 2017
- Cure Can Be Expected Now for Colon Cancer Due to Advances in Pharmacotherapy: Oncologist
July 5, 2017
- Long-Term Safety of PCSK9 Inhibitors Remains to Be Determined: New Atherosclerosis Prevention Guidelines
July 4, 2017
- Japanese Society of Hypertension to Verify Results of SPRINT Study
June 14, 2017
- AbbVie’s Novel Hep C Treatment Achieves 100% SVR in Genotype 1 Hepatitis C Patients with Compensated Cirrhosis
June 13, 2017
- DPP-4 Inhibitor Prevents Deterioration in Cardiac Diastolic Function in Diabetes Patients: Research Sub-Analysis
May 26, 2017
- Will Formularies Spread in Japan? Some Don’t Think So, but MOF Push Might Give Impetus
May 23, 2017
- “Authorized Biosimilars” Could Be Priced at 50% of Originators: Prof.
May 23, 2017
- JDS, JGS Publish 1st Guideline for Treatment of Diabetes in the Elderly
May 22, 2017
- PI/II Study Suggests Efficacy of Eisai’s Anti-Fractalkine Antibody for RA
April 25, 2017
- Gastric Cancer Guidelines Likely to Recommend Opdivo in 3rd Line Settings
April 24, 2017
- Hepatology Society to Release Updated Hep C Guidelines Soon, Reflecting Ximency Use
March 3, 2017
- NCC to Begin IIT for Pediatric ALL with Velcade Plus 5 Drugs
February 23, 2017
- AMED Drafts Japan’s First Manual for Treatment of Mitochondrial Diseases
February 20, 2017
- PCSK9 Inhibitors More Effective than Statins at Lowering LDL-C: New Atherosclerosis Prevention Guidelines
January 31, 2017
- Zonisamide Investigator-Led Trial for Dementia Symptoms to Begin in April
January 27, 2017
ページ
Measures focusing on risk management should be necessary to prevent disruptions in API supplies, Prof. Hiroyuki Sakamaki of Kanagawa University…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Japan’s pharmaceutical industry has been in dire need of a shake-up, and as we continue to grapple with the COVID-19 pandemic, one thing is remarkably clear. It’s no longer business as usual, and we’re enjoying a front-row seat to some…